The EMILIN/Multimerin Family
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Human Periprostatic Adipose Tissue: Secretome from Patients With
CANCER GENOMICS & PROTEOMICS 16 : 29-58 (2019) doi:10.21873/cgp.20110 Human Periprostatic Adipose Tissue: Secretome from Patients With Prostate Cancer or Benign Prostate Hyperplasia PAULA ALEJANDRA SACCA 1, OSVALDO NÉSTOR MAZZA 2, CARLOS SCORTICATI 2, GONZALO VITAGLIANO 3, GABRIEL CASAS 4 and JUAN CARLOS CALVO 1,5 1Institute of Biology and Experimental Medicine (IBYME), CONICET, Buenos Aires, Argentina; 2Department of Urology, School of Medicine, University of Buenos Aires, Clínical Hospital “José de San Martín”, Buenos Aires, Argentina; 3Department of Urology, Deutsches Hospital, Buenos Aires, Argentina; 4Department of Pathology, Deutsches Hospital, Buenos Aires, Argentina; 5Department of Biological Chemistry, School of Exact and Natural Sciences, University of Buenos Aires, Buenos Aires, Argentina Abstract. Background/Aim: Periprostatic adipose tissue Prostate cancer (PCa) is the second most common cancer in (PPAT) directs tumour behaviour. Microenvironment secretome men worldwide. While most men have indolent disease, provides information related to its biology. This study was which can be treated properly, the problem consists in performed to identify secreted proteins by PPAT, from both reliably distinguishing between indolent and aggressive prostate cancer and benign prostate hyperplasia (BPH) disease. Evidence shows that the microenvironment affects patients. Patients and Methods: Liquid chromatography-mass tumour behavior. spectrometry-based proteomic analysis was performed in Adipose tissue microenvironment is now known to direct PPAT-conditioned media (CM) from patients with prostate tumour growth, invasion and metastases (1, 2). Adipose cancer (CMs-T) (stage T3: CM-T3, stage T2: CM-T2) or tissue is adjacent to the prostate gland and the site of benign disease (CM-BPH). Results: The highest number and invasion of PCa. -
Maturation, Playing Position and Genetic Variation
MATURATION, PLAYING POSITION AND GENETIC VARIATION: INJURY RISK FACTORS IN HIGH-LEVEL YOUTH SOCCER ELLIOTT C R HALL A thesis submitted in partial fulfilment of the requirements of Liverpool John Moores University for the degree of Doctor of Philosophy September 2019 ACKNOWLEDGEMENTS I wish to thank all those who have helped me in completing this PhD thesis, particularly my supervisory team. It has been a privilege to work with and learn from you all, and I am extremely grateful for the opportunity. I would like to express sincere gratitude to my Director of Studies, Dr. Rob Erskine, firstly for considering me for this PhD, and secondly for the exceptional guidance and support throughout the project. The work ethic, passion and drive you have displayed has motivated me to perform to the best of my ability, and my development has been guided by your valuable knowledge and experience. I hope the faith you displayed in nominating me for this project has been in some way repaid by the work we have achieved. I would like to thank Professor Barry Drust. I feel very fortunate to have had the opportunity to work under your guidance, particularly as this project involves a sport to which you have contributed so much invaluable knowledge and passion. Importantly, you have helped me to see things differently than I did at the start of this journey, and to see the ‘bigger picture’ in academic and personal life. It is also imperative to mention your support during participant recruitment, which contributed significantly to the success of this project. -
Searching for Novel Peptide Hormones in the Human Genome Olivier Mirabeau
Searching for novel peptide hormones in the human genome Olivier Mirabeau To cite this version: Olivier Mirabeau. Searching for novel peptide hormones in the human genome. Life Sciences [q-bio]. Université Montpellier II - Sciences et Techniques du Languedoc, 2008. English. tel-00340710 HAL Id: tel-00340710 https://tel.archives-ouvertes.fr/tel-00340710 Submitted on 21 Nov 2008 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. UNIVERSITE MONTPELLIER II SCIENCES ET TECHNIQUES DU LANGUEDOC THESE pour obtenir le grade de DOCTEUR DE L'UNIVERSITE MONTPELLIER II Discipline : Biologie Informatique Ecole Doctorale : Sciences chimiques et biologiques pour la santé Formation doctorale : Biologie-Santé Recherche de nouvelles hormones peptidiques codées par le génome humain par Olivier Mirabeau présentée et soutenue publiquement le 30 janvier 2008 JURY M. Hubert Vaudry Rapporteur M. Jean-Philippe Vert Rapporteur Mme Nadia Rosenthal Examinatrice M. Jean Martinez Président M. Olivier Gascuel Directeur M. Cornelius Gross Examinateur Résumé Résumé Cette thèse porte sur la découverte de gènes humains non caractérisés codant pour des précurseurs à hormones peptidiques. Les hormones peptidiques (PH) ont un rôle important dans la plupart des processus physiologiques du corps humain. -
MMRN1 Antibody (Monoclonal) (M02) Mouse Monoclonal Antibody Raised Against a Partial Recombinant MMRN1
10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 MMRN1 Antibody (monoclonal) (M02) Mouse monoclonal antibody raised against a partial recombinant MMRN1. Catalog # AT2883a Specification MMRN1 Antibody (monoclonal) (M02) - Product Information Application WB, E Primary Accession Q13201 Other Accession NM_007351 Reactivity Human Host mouse Clonality Monoclonal Isotype IgG2b Kappa Calculated MW 138110 MMRN1 Antibody (monoclonal) (M02) - Additional Information Antibody Reactive Against Recombinant Protein.Western Blot detection against Gene ID 22915 Immunogen (36.74 KDa) . Other Names Multimerin-1, EMILIN-4, Elastin microfibril interface located protein 4, Elastin microfibril interfacer 4, Endothelial cell multimerin, Platelet glycoprotein Ia*, 155 kDa platelet multimerin, p-155, p155, MMRN1, ECM, EMILIN4, GPIA*, MMRN Target/Specificity MMRN1 (NP_031377, 291 a.a. ~ 390 a.a) partial recombinant protein with GST tag. MW of the GST tag alone is 26 KDa. Detection limit for recombinant GST tagged MMRN1 is approximately 0.1ng/ml as a Dilution capture antibody. WB~~1:500~1000 Format MMRN1 Antibody (monoclonal) (M02) - Clear, colorless solution in phosphate Background buffered saline, pH 7.2 . Multimerin is a massive, soluble protein found Storage in platelets and in the endothelium of blood Store at -20°C or lower. Aliquot to avoid vessels. It is comprised of subunits linked by repeated freezing and thawing. interchain disulfide bonds to form large, variably sized homomultimers. Multimerin is a Precautions factor V/Va-binding protein and may function MMRN1 Antibody (monoclonal) (M02) is for as a carrier protein for platelet factor V. It may research use only and not for use in also have functions as an extracellular matrix diagnostic or therapeutic procedures. -
Supplementary Table 1: Adhesion Genes Data Set
Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like, -
Multimerin-2 Is a Ligand for Group 14 Family C-Type Lectins CLEC14A, CD93 and CD248 Spanning the Endothelial Pericyte Interface
OPEN Oncogene (2017) 36, 6097–6108 www.nature.com/onc ORIGINAL ARTICLE Multimerin-2 is a ligand for group 14 family C-type lectins CLEC14A, CD93 and CD248 spanning the endothelial pericyte interface KA Khan1, AJ Naylor2, A Khan1, PJ Noy1, M Mambretti1, P Lodhia1, J Athwal1, A Korzystka1, CD Buckley2, BE Willcox3, F Mohammed3 and R Bicknell1 TheC-typelectindomaincontaininggroup14familymembers CLEC14A and CD93 are proteins expressed by endothelium and are implicated in tumour angiogenesis. CD248 (alternatively known as endosialin or tumour endothelial marker-1) is also a member of this family and is expressed by tumour-associated fibroblasts and pericytes. Multimerin-2 (MMRN2) is a unique endothelial specific extracellular matrix protein that has been implicated in angiogenesis and tumour progression. We show that the group 14 C-type lectins CLEC14A, CD93 and CD248 directly bind to MMRN2 and only thrombomodulin of the family does not. Binding to MMRN2 is dependent on a predicted long-loop region in the C-type lectin domainandisabrogatedbymutationwithinthedomain. CLEC14A and CD93 bind to the same non-glycosylated coiled-coil region of MMRN2, but the binding of CD248 occurs on a distinct non-competing region. CLEC14A and CD248 can bind MMRN2 simultaneously and this occurs at the interface between endothelium and pericytes in human pancreatic cancer. A recombinant peptide of MMRN2 spanning the CLEC14A and CD93 binding region blocks CLEC14A extracellular domain binding to the endothelial cellsurfaceaswellasincreasingadherenceofhumanumbilical vein endothelial cells to the active peptide. This MMRN2 peptide is anti-angiogenic in vitro and reduces tumour growth in mouse models. These findings identify novel protein interactions involving CLEC14A, CD93 and CD248 with MMRN2 as targetable components of vessel formation. -
Supplementary Table S4. FGA Co-Expressed Gene List in LUAD
Supplementary Table S4. FGA co-expressed gene list in LUAD tumors Symbol R Locus Description FGG 0.919 4q28 fibrinogen gamma chain FGL1 0.635 8p22 fibrinogen-like 1 SLC7A2 0.536 8p22 solute carrier family 7 (cationic amino acid transporter, y+ system), member 2 DUSP4 0.521 8p12-p11 dual specificity phosphatase 4 HAL 0.51 12q22-q24.1histidine ammonia-lyase PDE4D 0.499 5q12 phosphodiesterase 4D, cAMP-specific FURIN 0.497 15q26.1 furin (paired basic amino acid cleaving enzyme) CPS1 0.49 2q35 carbamoyl-phosphate synthase 1, mitochondrial TESC 0.478 12q24.22 tescalcin INHA 0.465 2q35 inhibin, alpha S100P 0.461 4p16 S100 calcium binding protein P VPS37A 0.447 8p22 vacuolar protein sorting 37 homolog A (S. cerevisiae) SLC16A14 0.447 2q36.3 solute carrier family 16, member 14 PPARGC1A 0.443 4p15.1 peroxisome proliferator-activated receptor gamma, coactivator 1 alpha SIK1 0.435 21q22.3 salt-inducible kinase 1 IRS2 0.434 13q34 insulin receptor substrate 2 RND1 0.433 12q12 Rho family GTPase 1 HGD 0.433 3q13.33 homogentisate 1,2-dioxygenase PTP4A1 0.432 6q12 protein tyrosine phosphatase type IVA, member 1 C8orf4 0.428 8p11.2 chromosome 8 open reading frame 4 DDC 0.427 7p12.2 dopa decarboxylase (aromatic L-amino acid decarboxylase) TACC2 0.427 10q26 transforming, acidic coiled-coil containing protein 2 MUC13 0.422 3q21.2 mucin 13, cell surface associated C5 0.412 9q33-q34 complement component 5 NR4A2 0.412 2q22-q23 nuclear receptor subfamily 4, group A, member 2 EYS 0.411 6q12 eyes shut homolog (Drosophila) GPX2 0.406 14q24.1 glutathione peroxidase -
Identification of the Rassf3 Gene As a Potential Tumor Suppressor
Clemson University TigerPrints All Dissertations Dissertations 12-2006 Identification of the Rassf3 Gene as a Potential Tumor Suppressor Responsible for the Resistance to Mammary Tumor Development in MMTV/ neu Transgenic Mice Isabelle Jacquemart Clemson University, [email protected] Follow this and additional works at: https://tigerprints.clemson.edu/all_dissertations Part of the Microbiology Commons Recommended Citation Jacquemart, Isabelle, "Identification of the Rassf3 Gene as a Potential Tumor Suppressor Responsible for the Resistance to Mammary Tumor Development in MMTV/neu Transgenic Mice" (2006). All Dissertations. 26. https://tigerprints.clemson.edu/all_dissertations/26 This Dissertation is brought to you for free and open access by the Dissertations at TigerPrints. It has been accepted for inclusion in All Dissertations by an authorized administrator of TigerPrints. For more information, please contact [email protected]. IDENTIFICATION OF THE Rassf3 GENE AS A POTENTIAL TUMOR SUPPRESSOR RESPONSIBLE FOR THE RESISTANCE TO MAMMARY TUMOR DEVELOPMENT IN MMTV/neu TRANSGENIC MICE A Dissertation Presented to the Graduate School of Clemson University In Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy Microbiology by Isabelle C. Jacquemart December 2006 Accepted by: Dr. Wen Y. Chen, Committee Chair Dr. Charles D. Rice Dr. Lyndon L. Larcom Dr. Lesly Temesvari i ABSTRACT The MMTV/neu transgenic mouse line is a well-documented animal model for studying HER2/neu-related breast cancer. It has been reported that a small percentage, approximately 20%, of the virgin female MMTV/neu mice seems resistant to the development of mammary gland adenoma, despite the overexpression of the neu oncogene. To identify the factors that are responsible for the tumor resistance in these MMTV/neu female transgenic mice, comparative genetic profiling was used to screen the alterations in gene expression in the mammary gland. -
TSPAN9 and EMILIN1 Synergistically Inhibit the Migration and Invasion Of
Qi et al. BMC Cancer (2019) 19:630 https://doi.org/10.1186/s12885-019-5810-2 RESEARCHARTICLE Open Access TSPAN9 and EMILIN1 synergistically inhibit the migration and invasion of gastric cancer cells by increasing TSPAN9 expression Yaoyue Qi1, Jing Lv2, Shihai Liu3, Libin Sun2, Yixuan Wang1, Hui Li1, Weiwei Qi2* and Wensheng Qiu2* Abstract Background: Globally, the incidence and mortality rates of gastric cancer are high, and its poor prognosis is closely related to tumor recurrence and metastasis. Therefore, the molecular mechanisms associated with the migration and invasion of gastric cancer cells are important for gastric cancer treatment. Previously, TSPAN9 has been reported to inhibit gastric cancer cell migration; however, the underlying molecular mechanism remains unclear. Methods: Human gastric adenocarcinoma cell lines, SGC7901 and AGS, were cultured in vitro. TSPAN9 expression was determined by RT-PCR, western blot analysis, and immunohistochemistry in gastric cancer and tumor-adjacent tissues. Following the over-expression and knockdown of TSPAN9, wound healing and cell invasion assays were performed and EMT-related protein expression was evaluated to analyze the invasion and migration of gastric cancer cells. TSPAN9 expression and the invasion and metastasis of gastric cancer cells were observed by the functional assays following EMILIN1 over-expression. Results: Inhibiting TSPAN9 expression significantly promoted the migration and invasion of gastric cancer cells. In addition, immunofluorescence co-localization and co-immunoprecipitation analysis revealed closely related expression of EMILIN1 and TSPAN9. Moreover, EMILIN1 can synergistically boost the tumor suppressive effect of TSPAN9, which may be produced by promoting TSPAN9 expression. Conclusions: We have demonstrated that EMILIN1 induces anti-tumor effects by up-regulating TSPAN9 expression in gastric cancer. -
Inactivation of EMILIN-1 by Proteolysis and Secretion in Small Extracellular Vesicles Favors Melanoma Progression and Metastasis
International Journal of Molecular Sciences Article Inactivation of EMILIN-1 by Proteolysis and Secretion in Small Extracellular Vesicles Favors Melanoma Progression and Metastasis Ana Amor López 1, Marina S. Mazariegos 1, Alessandra Capuano 2 , Pilar Ximénez-Embún 3, Marta Hergueta-Redondo 1, Juan Ángel Recio 4 , Eva Muñoz 5,Fátima Al-Shahrour 6 , Javier Muñoz 3, Diego Megías 7, Roberto Doliana 2, Paola Spessotto 2 and Héctor Peinado 1,* 1 Microenvironment and Metastasis Laboratory, Molecular Oncology Programme, Spanish National Cancer Research Center (CNIO), 28029 Madrid, Spain; [email protected] (A.A.L.); [email protected] (M.S.M.); [email protected] (M.H.-R.) 2 Unit of Molecular Oncology, Centro di Riferimento Oncologico di Aviano (CRO), Department of Advanced Cancer Research and Diagnostics, IRCCS, I-33081 Aviano, Italy; [email protected] (A.C.); [email protected] (R.D.); [email protected] (P.S.) 3 Proteomics Unit—ProteoRed-ISCIII, Spanish National Cancer Research Centre (CNIO), 28029 Madrid, Spain; [email protected] (P.X.-E.); [email protected] (J.M.) 4 Biomedical Research in Melanoma-Animal Models and Cancer Laboratory, Vall d’Hebron Research Institute VHIR-Vall d’Hebron Hospital Barcelona-UAB, 08035 Barcelona, Spain; [email protected] 5 Clinical Oncology Program, Vall d’Hebron Institute of Oncology-VHIO, Vall d’Hebron Hospital, Barcelona-UAB, 08035 Barcelona, Spain; [email protected] Citation: Amor López, A.; 6 Bioinformatics Unit, Structural Biology Programme, Spanish National Cancer Research Centre (CNIO), Mazariegos, M.S.; Capuano, A.; 28029 Madrid, Spain; [email protected] Ximénez-Embún, P.; Hergueta- 7 Confocal Microscopy Unit, Biotechnology Programme, Spanish National Cancer Research Center (CNIO), Redondo, M.; Recio, J.Á.; Muñoz, E.; 28029 Madrid, Spain; [email protected] Al-Shahrour, F.; Muñoz, J.; Megías, D.; * Correspondence: [email protected] et al. -
EGFL7 Meets Mirna-126: an Angiogenesis Alliance
- http://vascularcell.com/ REVIEW | OPEN ACCESS EGFL7 meets miRNA-126: an angiogenesis alliance Journal of Angiogenesis Research 2:9 | DOI: 10.1186/2040-2384-2-9 | © Li et al.; licensee Publiverse Online S.R.L. 2010 Received: 21 Apr 2010 | Accepted: 8 Apr 2010 | Published: 8 Apr 2010 Nikolic Iva, Plate Karl-Heinz, Schmidt Mirko HH@ + Contributed equally@ Corresponding author Abstract Blood vessels form de novo through the tightly regulated programs of vasculogenesis and angiogenesis. Both processes are distinct but one of the steps they share is the formation of a central lumen, when groups of cells organized as vascular cords undergo complex changes to achieve a tube-like morphology. Recently, a protein termed epidermal growth factor-like domain 7 (EGFL7) was described as a novel endothelial cell-derived factor involved in the regulation of the spatial arrangement of cells during vascular tube assembly. With its impact on tubulogenesis and vessel shape EGFL7 joined the large family of molecules governing blood vessel formation. Only recently, the molecular mechanisms underlying EGFL7's effects have been started to be elucidated and shaping of the extracellular matrix (ECM) as well as Notch signaling might very well play a role in mediating its biological effects. Further, findings in knock-out animal models suggest miR-126, a miRNA located within the egfl7 gene, has a major role in vessel development by promoting VEGF signaling, angiogenesis and vascular integrity. This review summarizes our current knowledge on EGFL7 and miR-126 and we will discuss the implications of both bioactive molecules for the formation of blood vessels. -
Data Supplement
Cell-specific ablation of Hsp47 defines the collagen producing cells in the injured heart Hadi Khalil,1 Onur Kanisicak,1,2 Ronald J. Vagnozzi,1Anne Katrine Johansen,1 Bryan D. Maliken,1 Vikram Prasad,1 Justin G. Boyer,1 Matthew J. Brody,1 Tobias Schips,1 Katja K. Kilian,1 Robert N. Correll,1,3 Kunito Kawasaki,4 Kazuhiro Nagata,4 Jeffery D. Molkentin1,5 1Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, Ohio, USA 2Department of Pathology, University of Cincinnati, Cincinnati, Ohio, USA 3Department of Biological Sciences, University of Alabama, Tuscaloosa, Alabama, USA 4Institute for Protein Dynamics, Kyoto Sangyo University, Kyoto, Japan 5Howard Hughes Medical Institute, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA Data Supplement -Supplemental Figures 1-7 -Supplemental Tables 1-3 Culture A Adβgal AdCre 100 µm CHP eGFP R26eGFP; Postn-MCM B 0.05 Hearts # R26eGFP; Hsp47fl/fl-Postn-MCM 0.04 * Supplemental Figure 1. Deletion of Hsp47 leads to collagen 0.03 aggregates in cultured fibroblasts and cell death in vivo. (A) Adult primary heart fibroblasts were isolated from R26eGFP Hsp47-loxP 0.02 TUNEL (%) TUNEL * targeted mice and infected with Adβgal or AdCre. Seventy-two hours later cells were processed for collagen-hybridizing peptide 0.01 immunofluorescence (red), showing collagen aggregates when Hsp47 was deleted, which was not observed in Adβgal controls. Fibroblast 0 Sham identity was shown by eGFP staining in the AdCre infected conditions. TAC Three separate experiments gave similar results. (B) TUNEL staining showing cell death levels in hearts of the indicated mice after 4 weeks post TAC.